How can we help?


Bioneer assists clients in the pre-clinical and early clinical phases with production of recombinant proteins in a variety of mammalian cell systems, with access to existing or development of novel functional assays based upon mammalian cells as well as general technology development, e.g. bioreactor evaluation, biobanking, and cell handling. In fact, we can support our clients in the entire process of bringing a novel biologic compound from the laboratory through pre-clinical evaluation for functionality and safety.


Bioneer offers evaluation of compounds using mainly three cell systems 1) Primary dendritic cells (human and murine) 2) Peripheral blood mononuclear cells (PBMCs) and 3) cell line based models. We provide services in our model systems in the discovery process (mainly evaluation of mechanism of action and immune modulation and suppression of specific inflammatory responses) as well as activities involved in the development process (mainly evaluation of safety of IV administered drugs, and assessment of potency).


Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.


Turning an active compound into a drug product

Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.

Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark.


Bioneer offers a range of services related to the identification, validation and documentation of disease relevant biomarkers and drug targets. These services comprise a toolbox of molecular methods that will facilitate the pre-clinical development of both biomarkers, drug-targets and active compounds, which will be useful in diagnostic, prognostic, and therapeutic contexts, and, furthermore, serve as effective means to optimize clinical trial designs.


The Dynamic Gastric Model is the first true "dynamic" in-vitro model of the human stomach that fully replicates the complex biochemical conditions and the array of gastric forces crucial for the prediction of oral pharmaceuticals and food products


Bioneer på

Vi ønsker dit input til at forme Bioneers R&D aktiviteter og services i fremtiden. Bioneer har lagt 8 forslag til fremtidens services ud på sitet BedreInnovation (se mere her).

Read more
Bioneer publish article in Biozoom with the BRAINStem partners
Bioneer publish exciting article about disease modelling in the magazine Biozoom together with the BRAINStem Center partners.
Read more
Read ALL news

Ongoing inNovation consortia:

A Danish initiative to enhance our understanding of the complexity of cancer diseases.
Read more

Meet us at:

Danish Society for Neuroscience (DSfN)

Benjamin Scmid, PhD, from Bioneer is invited to give a talk on using gene editing technologies to correct mutations causing Parkinson Disease

Read more
IATI Biomed 2015

Bioneer will participate at IATI Biomed 2015 in Tel Aviv on May 12-14.

Read more
Danish Stem Cell Society (DASCS)

Bioneer will present their disease modelling platforms and exciting stem cell research at DASCS on June 4-5

Read more
International Society for Stem Cell Research (ISSCR)

Bioneer will present their disease modelling platforms and exciting stem cell research at ISSCR on June 24-27

Read more
Other places to meet us